

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 73906

Title: Endoscopic ultrasound-guided Injectable Therapy for Pancreatic Cancer: A

Systematic Review

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05458765

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Research Fellow

Reviewer's Country/Territory: China

Author's Country/Territory: United States

Manuscript submission date: 2021-12-10

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-12-21 21:17

Reviewer performed review: 2021-12-25 02:59

Review time: 3 Days and 5 Hours

Scientific quality	[Y] Grade A: Excellent [] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[Y] Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[Y] Accept (High priority) [] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Re-review	[Y]Yes []No



Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous
statements	Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

This is a MS entitled 'Endoscopic ultrasound-guided Injectable Therapy for Pancreatic Cancer: A Systematic Review', which summarizes the application of EUS-FNI in delivering anti-tumor immune cells or reagents to PDAC tissues. PDAC is a highly lethal malignance with a lower response to different theraputics. EUS-FNI has been shown as an effective method in treating PDAC. The structure and flow of this review with a systemic and broad coverage on this very topic facilitate reading and understating. The up-to-date information and literature summarized and presented in this review are very timely and interesting to the filed. It is educational.



PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 73906

Title: Endoscopic ultrasound-guided Injectable Therapy for Pancreatic Cancer: A

Systematic Review

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05130847

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Assistant Professor

Reviewer's Country/Territory: China

Author's Country/Territory: United States

Manuscript submission date: 2021-12-10

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-12-17 15:07

Reviewer performed review: 2021-12-28 16:31

Review time: 11 Days and 1 Hour

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[Y] Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	 [] Accept (High priority) [Y] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Re-review	[Y]Yes []No



Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous
statements	Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

This study systematic reviewed the progress made with EUS-guided injectable therapies in the treatment of PDAC. The results showed that current data demonstrate that EUS-guided injectable therapies are safe for the treatment of PDAC. Further studies, especially RCT studies, are required to confirm the adverse events and potential efficacy. It is best to include a list of main adverse events (AEs) and clinical efficacy in Table 1.